Table 1

Baseline patient characteristics, echocardiographic parameters and treatment decisions by number of comorbidities

All patients
0 comorbidities*
One comorbidity*
≥2 comorbidities*
P value across comorbidity groups
Age (years)77.9±10.075.7±10.779.4±9.081.4±7.8<0.001
Female gender48.
Severe frailty†<0.001
EuroSCORE I (%)15.6±13.99.5±8.217.9±12.826.8±18.5<0.001
EuroSCORE II (%)4.0±5.02.2±3.04.7±4.78.2±7.2<0.001
Echocardiographic valve parameters
 Indexed AV area (cm2/m2)0.40±5.00.41±0.110.39±0.100.37±0.11<0.001
 Mean AV gradient (mm Hg)47.1±14.750.0±13.345.4±14.842.2±16.3<0.001
 Mitral regurgitation grade III/IV10.75.213.620.4<0.001
 Tricuspid regurgitation grade III/IV7.<0.001
 Indexed LV mass (g/m2)132.6±40.9126.7±38.0134.4±41.1147.6±44.7<0.001
Symptomatic status‡ (%)80.373.684.491.8<0.001
Severe symptomatic status§ (%)51.740.858.470.1<0.001
Decision to perform AVR69.067.271.569.30.186
 AVR performed within 3 months56.351.561.560.5<0.001
 Time to intervention (days)33.0±34.735.7±36.130.5±33.630.8±32.30.012
Decision to perform TAVI45.035.454.057.0<0.001
 TAVI performed within 3 months38.028.347.050.5<0.001
 Time to intervention (days)29.2±34.230.0±36.429.2±33.627.5±31.00.755
Decision to perform SAVR24.031.917.412.3<0.001
 SAVR performed within 3 months18.323.314.410.0<0.001
 Time to intervention (days)40.7±34.542.4±34.734.5±33.446.5±34.40.037
Decision not to perform AVR27.629.125.726.5<0.001
  • *LVEF <50%, CKD, AF or COPD.

  • †Defined as an inability to walk 5 m in ≤6 s and/or to perform activities of daily living.24

  • ‡Defined as chest pain, shortness of breath and/or dizziness on exertion/syncope.

  • §Defined as CCS class III or IV angina, NYHA class III/IV and/or dizziness on exertion/syncope.

  • AF, atrial fibrillation; AV, aortic valve; AVA, aortic valve area; AVR, aortic valve replacement; CCS, Canadian Cardiovascular Society; CKD, chronic kidney disease ; COPD, chronic obstructive pulmonary disease; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SAVR, surgical AVR; TAVI, transcatheter aortic valve implantation .